<DOC>
	<DOCNO>NCT02466815</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability 2 prototype G-025 tablet compare current G-018 tablet .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability JNJ-42756493 Tablets</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-period , randomize ( study drug assign chance ) , single-dose , 3-way crossover study . The study consist 21-day screening period , 3 open-label treatment period minimum 21 ( +-2 ) -day washout dos , end-of-study assessment 10 ( +-2 ) day last dose . The duration study approximately 3 month . Participants randomize 1 6 treatment sequence follow : Treatment sequence 1=ABC , 2=BCA , 3=CAB , 4=ACB , 5=BAC AND 6=CBA . Treatment A=JNJ-42756493 current clinical formulation , 10 milligram ( mg ) ( 2 tablet 5 mg ) . Treatment B= JNJ-42756493 Prototype Formulation I ( G-025 ) , 10 mg ( 2 tablet 5 mg ) Treatment C=JNJ-42756493 Prototype Formulation II ( G-025 ) , 10 mg ( 2 tablet 5 mg ) . Blood sample collect determine pharmacokinetic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Participants willing adhere prohibition restriction specify protocol Woman must either : postmenopausal ( great ( &gt; ) 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone ( follicle stimulate hormone [ FSH ] ) &gt; 40 international unit per litre [ IU/L ] ) ; surgically sterile Woman must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screen negative urine pregnancy test Day 1 treatment period Woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction study 3 month receive last dose study drug . Man sexually active woman childbearing potential vasectomy , must agree use highly effective method contraception deem appropriate investigator donate sperm study 3 month receive last dose study drug Participants history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude subject could interfere interpretation study result Participants history current evidence ophthalmic disorder , central serous retinopathy retinal vein occlusion , active wet age relate macular degeneration , diabetic retinopathy macular edema , uncontrolled glaucoma , corneal pathology keratitis , keratoconjunctivitis , keratopathy , corneal abrasion , inflammation ulceration Participants clinically significant abnormal value hematology , clinical chemistry , urinalysis screen Day 1 Period 1 deem appropriate investigator Participants clinically significant abnormal physical examination , vital sign , 12lead electrocardiogram ( ECG ) screen Day 1 Period 1 deem appropriate investigator Participants use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol hormonal replacement therapy within 14 day first dose study drug schedule completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42756493</keyword>
</DOC>